New and enhanced features of Planmed Verity® receive FDA approval

The U.S. Food and Drug Administration (FDA) has issued an approval letter for the new features and intended uses of the Planmed Verity® CBCT scanner. Planmed is very pleased to bring these exciting improvements to the U.S. market.

Planmed Verity

The U.S. Food and Drug Administration (FDA) issued an approval letter for the new features and intended uses of the Planmed Verity® orthopedic imaging solution on November 30th, 2018.

The improved Planmed Verity now offers enhanced image quality as well as new options for head and neck imaging, the Planmeca Ultra Low Dose™ imaging protocol for lower patient doses, and Planmeca CALM™ algorithm for motion artifact correction.

“We are excited to release the improved, XR-29 compliant Planmed Verity with its new dental and ENT imaging options. These features are something our customers have requested, and we are happy to answer their needs,” says Johan Moed, National Sales Manager of Planmed USA. “This unit is now more versatile than ever before. It is an easy-to-use and cost-effective solution, which makes it a great tool for any imaging center, clinic or hospital.”

The new enhancements include the iterative Planmeca CALM algorithm, which reduces artifacts caused by patient movement. The groundbreaking Planmeca CALM is especially useful in challenging weight-bearing examinations in which patients have a tendency to move. Meanwhile, the innovative Planmeca Ultra Low Dose™ (ULD) imaging protocol enables reducing Planmed Verity’s already low effective patient doses even further – without compromising diagnostic image quality.

“The work done on the iterative algorithms further strengthens our commitment to offering high quality imaging solutions with extremely low patient radiation doses. We are delighted to start delivering scanners with these exciting features to our customers in the United States,” Moed concludes.

For more information, please contact:
Mr. Johan Moed
National Sales Manager, Planmed USA

Planmed Oy and Planmeca Group
Planmed Oy develops, manufactures, and markets advanced imaging equipment and accessories for mammography and orthopedic imaging. Planmed's extensive mammography product range covers digital and analog units and digital breast tomosynthesis (DBT) systems, stereotactic biopsy devices, and breast positioning systems for early detection of breast cancer. For orthopedic 3D imaging Planmed offers low dose extremity CT imaging for quicker, easier and more accurate diagnosis at point-of-care. Planmed Oy is strongly committed to R&D and design and the company exports more than 98% of its production to over 70 countries worldwide. Planmed Oy was established in 1989 and the company’s headquarters are located in Helsinki, Finland. Planmed Oy is part of Planmeca Group. The Group's turnover in 2016 was MEUR 730, employing nearly 2,700 people worldwide.